4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 新闻动态 >
新闻详情
MedKoo Biosciences/HJC-0123/406528/50mg
来自 : 发布时间:2025-01-16
Downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values. Furthermore, HJC-0123 significantly suppressed estrogen receptor (ER)-negative breast cancer MDA-MB-231 xenograft tumor growth in vivo (p.o.), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy.

MedKoo Cat#: 406528 Name: HJC-0123 CAS#: 1430420-02-2 Chemical Formula: C24H16N2O3S Exact Mass: 412.08816 Molecular Weight: 412.46 Elemental Analysis: C, 69.89; H, 3.91; N, 6.79; O, 11.64; S, 7.77

Synonym: HJC0123; HJC 0123; HJC-0123.

IUPAC/Chemical Name: N-(1,1-dioxidobenzo[b]thiophen-6-yl)-2-phenylquinoline-4-carboxamide

InChi Key: ZUYCAEIBKWUMND-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H16N2O3S/c27-24(25-18-11-10-17-12-13-30(28,29)23(17)14-18)20-15-22(16-6-2-1-3-7-16)26-21-9-5-4-8-19(20)21/h1-15H,(H,25,27)

SMILES Code: O=C(C1=CC(C2=CC=CC=C2)=NC3=CC=CC=C13)NC4=CC=C(C=CS5(=O)=O)C5=C4

Technical Data

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code: 293490

Additional Information

        

References

1: Chen H, Yang Z, Ding C, Chu L, Zhang Y, Terry K, Liu H, Shen Q, Zhou J. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur J Med Chem. 2013Apr;62:498-507. doi: 10.1016/j.ejmech.2013.01.023. Epub 2013 Jan 26. PubMed PMID: 23416191; PubMed Central PMCID: PMC3750725.

本文链接: http://medkoo.immuno-online.com/view-1457205738.html

发布于 : 2025-01-16 阅读()